Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. Lenvatinib inhibited Flt-1 (VEGFR1), KDR (VEGFR2) and Flt-4 (VEGFR3) with IC50 values of 22, 4.0 and 5.2 nM, respectively. Lenvatinib has potent antitumor activity against human H146, a SCLC cell line in mice based on angiogenesis inhibition via both KDR and KIT signaling, compared to single inhibition of either KDR or KIT signaling.

KEYWORDS: Lenvatinib | supplier | RTK inhibitor | E7080 | E 7080 | E-7080' | CAS [417716-92-8] | [857890-39-2] | VEGF | VEGFR | Inhibitor | Receptors